Literature DB >> 14581420

Time course and predictors of symptoms after primary prostate cancer therapy.

James A Talcott1, Judithy Manola, Jack A Clark, Irving Kaplan, Clair J Beard, Sonya P Mitchell, Ronald C Chen, Michael P O'Leary, Philip W Kantoff, Anthony V D'Amico.   

Abstract

PURPOSE: Understanding the distinctive patterns of treatment-related dysfunction after alternative initial treatments for early prostate cancer (PC) may improve patients' choice of treatment and later help them adjust to its consequences. We characterized the time course of treatment complications while adjusting for potentially confounding pretreatment factors hindering other observational studies. PATIENTS AND METHODS: In a prospective cohort study of 417 men we assessed urinary, bowel, and sexual function from before primary treatment to 24 months after. To control for potential confounding, we measured sociodemographic and PC prognostic factors, medical comorbidity, and pretreatment function commonly affected by PC and its treatment.
RESULTS: Patients who underwent external beam radiotherapy (EBRT), radical prostatectomy (RP), and brachytherapy (BT) differed significantly in sociodemographic factors, cancer prognostic factors, and pretreatment symptom status, especially sexual function. Urinary incontinence increased sharply after RP, while bowel problems and urinary irritation/obstruction rose after EBRT and BT. Sexual dysfunction increased in all patients, particularly after radical prostatectomy, and nerve-sparing surgical technique had little apparent benefit. There was no change in urinary function and little change in overall bowel function after 12 months, but the time course of sexual dysfunction varied by treatment and, for bowel function, by symptom. Multiple regression modeling confirmed that treatment influences all 24-month outcomes, but residual confounding persisted.
CONCLUSION: Pretreatment function and the primary treatment modality for early stage PC strongly predict the affected organ systems and time course of dysfunction. With this information, patients and their physicians may refine their choice of treatment and better anticipate its consequences.

Entities:  

Mesh:

Year:  2003        PMID: 14581420     DOI: 10.1200/JCO.2003.01.199

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  41 in total

1.  Prediction of erectile function following treatment for prostate cancer.

Authors:  Mehrdad Alemozaffar; Meredith M Regan; Matthew R Cooperberg; John T Wei; Jeff M Michalski; Howard M Sandler; Larry Hembroff; Natalia Sadetsky; Christopher S Saigal; Mark S Litwin; Eric Klein; Adam S Kibel; Daniel A Hamstra; Louis L Pisters; Deborah A Kuban; Irving D Kaplan; David P Wood; Jay Ciezki; Rodney L Dunn; Peter R Carroll; Martin G Sanda
Journal:  JAMA       Date:  2011-09-21       Impact factor: 56.272

2.  Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study.

Authors:  Melissa S Y Thong; Lonneke van de Poll-Franse; Richard M Hoffman; Peter C Albertsen; Ann S Hamilton; Janet L Stanford; David F Penson
Journal:  BJU Int       Date:  2010-11-11       Impact factor: 5.588

3.  Trajectories and predictors of symptom occurrence, severity, and distress in prostate cancer patients undergoing radiation therapy.

Authors:  Katie Knapp; Bruce Cooper; Theresa Koetters; Janine Cataldo; Anand Dhruva; Steven M Paul; Claudia West; Bradley E Aouizerat; Christine Miaskowski
Journal:  J Pain Symptom Manage       Date:  2012-07-07       Impact factor: 3.612

Review 4.  Management of the complications of external beam radiotherapy and brachytherapy.

Authors:  Stacy Loeb; Robert B Nadler
Journal:  Curr Urol Rep       Date:  2006-05       Impact factor: 3.092

5.  Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer.

Authors:  George Rodrigues; Xiaomei Yao; D Andrew Loblaw; Michael Brundage; Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

6.  Patient-Reported GI Outcomes in Patients With Anal Cancer Receiving Modern Chemoradiation.

Authors:  Ramez Kouzy; Joseph Abi Jaoude; Daniel Lin; Molly B El Alam; Bruce D Minsky; Eugene J Koay; Prajnan Das; Emma B Holliday; Ann H Klopp; Lauren E Colbert; Cullen M Taniguchi
Journal:  JCO Oncol Pract       Date:  2020-07-01

7.  Robot-assisted laparoscopic radical prostatectomy after previous open transvesical adenomectomy.

Authors:  Alfredo Maria Bove; Emanuela Altobelli; Federico Sergi; Maurizio Buscarini
Journal:  J Robot Surg       Date:  2013-01-18

8.  Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.

Authors:  Phillip J Gray; Jonathan J Paly; Beow Y Yeap; Martin G Sanda; Howard M Sandler; Jeff M Michalski; James A Talcott; John J Coen; Daniel A Hamstra; William U Shipley; Stephen M Hahn; Anthony L Zietman; Justin E Bekelman; Jason A Efstathiou
Journal:  Cancer       Date:  2013-02-22       Impact factor: 6.860

Review 9.  Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.

Authors:  Sarah L Kerns; Harry Ostrer; Barry S Rosenstein
Journal:  Cancer Discov       Date:  2014-01-17       Impact factor: 39.397

10.  Race, healthcare access and physician trust among prostate cancer patients.

Authors:  Young Kyung Do; William R Carpenter; Pamela Spain; Jack A Clark; Robert J Hamilton; Joseph A Galanko; Anne Jackman; James A Talcott; Paul A Godley
Journal:  Cancer Causes Control       Date:  2009-09-24       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.